Skip to main content

Table 1 Clinicopathologic characteristics of triple negative breast cancer

From: Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer

  n (%)
Age(years)° 48.85 ± 11.49
Age groups
  ≤ 30 years 5(3.3)
 31–50 years 84(56)
  > 50 years 61(40.7)
 Tumor size(Unit)° 4.01 ± 1.99
Tumor stage/tumor size
 T1 7(4.7)
 T2 116(77.3)
 T3/T4 27(18)
 Ki67 Index (%) 46.89 ± 23.88
ki67 index groups
  ≤ 15% 17(11.3)
 16–24% 8(5.3)
 25–44% 45(30)
  > 44% 80(53.3)
Nodal Status
 Positive 64(42.7)
 Negative 86(57.3)
Nodal Stage
 No 88(58.7)
 N1 30(20)
 N2 13(8.7)
 N3 19(12.7)
Histological Subtypes
 IDC 127(84.7)
 Papillary 6(4)
 Medullary 1(0.7)
 Metaplastic 14(9.3)
 Mixed 2(1.3)
Tumor Grade
 Grade-I 1(0.7)
 Grade-II 19(12.7)
 Grade-III 130(86.7)
Lymphocytic infiltration
 Absent 15(10)
 Moderate 110(73.3)
 Severe 25(16.7)
Lymhovascular Invasion
 Present 36(24)
 Absent 114(76)
Dermal Lymphatic invasion
 Present 10(6.7)
 Absent 140(93.3)
Type of Surgery
 Modified radical mastectomy 94(62.7)
 Simple mastectomy with sentinel lymph node dissection 42(28)
 Wide local excision 14(9.3)
Necrosis
 Absent 21(14)
 Moderate 90(60)
 Severe 39(26)
Fibrosis
 Mild 42(28)
 Moderate 88(58.7)
 Severe 20(13.3)
Insitu component
 Present 58(38.7)
 Absent 92(61.3)
Pagetoid Spread
 Present 2(1.3)
 Absent 148(98.7)
Perinodal extension
 Present 30(20)
 Absent 120(80)
Triple negative phenotype
 Basal 16(10.7)
 Non-basal 134(89.3)
Adjuvant chemotherapy (n = 101)
 Yes 98(97)
 No 3(3)
Adjuvant radiation(n = 101)
 Yes 69(68.3)
 No 32(31.7)
Recurrence(n = 101)
 Yes 18(17.8)
 No 83(82.2)
  1. Mean ± SD
\